Cell Culture Reagents Market by Product (Growth Factors and Cytokines, Supplement, Cryoprotective, Antibiotic, Buffer), Application (Bioproduction (Antibody, Protein, Vaccine), Research, Diagnostics), End User (Pharma, Academic) - Global Forecast to 2029

The Cell Culture Reagents Market is expected to reach $11.04 billion by 2029, at a CAGR of 12.8% from 2022 to 2029. Different types of cell culture reagents support cell growth and the consistency of cell culture. Supplements provide additional nutrients to the cells growing in the culture, such as antioxidants, amino acid solutions, and growth factors. Inorganic salts such as calcium chloride dehydrate, potassium chloride, and sodium chloride are used as balanced salt solutions to maintain the medium at physiological pH, intracellular, and extracellular osmotic pressure. All the reagents used in cell cultures are of high quality.

The growth of this market is driven by factors such as the rising demand for monoclonal bodies, the increasing prevalence of chronic diseases, funding for cell-based research, and an increase in R&D spending in the life science sector. Furthermore, the growing adoption of 3D cell culture, the growth potential of personalized medicine, and emerging economies are expected to provide significant opportunities for the growth of this market. However, ethical concerns regarding cell biology research and reproducibility of results challenge the growth of the market upto a certain extent.

COVID-19 Pandemic Impact: Cell Culture Reagents Market

The COVID-19 pandemic raised worldwide awareness of the crucial role of scientific research in global health security. The governments and funding agencies worldwide allocated substantial resources to fund COVID-19-related research proposals. Funding kept the pace of the research activities stable and helped in the detailed understanding of the pandemic's effects on human health.

• In September 2021, the Australian Government provided USD 5 million to Walter and Eliza Hall Institute of Medical Research (Melbourne) to find a new, effective, safe antibody treatment to combat COVID-19. As of September 2021, the government has invested USD 96 million from the Medical Research Future Fund (MRFF) in COVID-19 research. This includes diagnostics, vaccine development, antiviral development, clinical trials, digital health research infrastructure, and human immune response to COVID-19 infection.

• As of May 2021, the U.S. and Germany were the largest COVID-19 vaccine R&D investors, where the amount invested was USD 2 billion and USD 1.5 billion, respectively. Private companies received most of the funding, with more than USD 900 million received by Moderna, Inc. (U.S.) and Janssen Pharmaceuticals (Belgium) and USD 800 million by Pfizer Inc. (U.S.) and BioNTech SE (Germany) (Source: Forbes article)
• In 2021, the National Institutes of Health (NIH) received USD 4.9 billion to fund important COVID-19 research on diagnostic tests, vaccines, and treatments.
• As of August 2020, the Government of Canada funded grants to 140 COVID-19 research projects, and the total investment reaching to USD 111.1 million.
• In 2020, CureVac N.V. (Germany) received initial funding of USD 8.3 million from Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate vaccine development against coronavirus.
• In 2020, Harvard University (U.S.) and Guangzhou Institute for Respiratory Health (China) partnered to discover COVID-19 therapies. The two institutes received funding of USD 115 million from China

The growing funding supported the research studies and the demand for cell culture reagents during the pandemic. The cell culture technique was useful for studying various coronavirus factors and antibody and vaccine production. Hence, the pandemic positively impacted the cell culture reagents market.

 Click here to: Get Free Sample Copy of this report 

Funding for Cell-based Research Drive Market Growth

Research studies help understand the response of cells towards any chemical and discover novel components which can be used for people's well-being globally. These studies are carried out for a long time as standardization is needed when finding novel components. Such studies require investment which further supports more wide innovations in the medical field. For instance:

• In December 2021, Novo Nordisk Foundation granted up to USD 355 million (EUR 300 million) for establishing an international research center focused on stem cell medicine. The center is a collaboration between the University of Copenhagen, Denmark, Murdoch Children’s Research Institute, Australia, and Leiden University Medical Center, The Netherlands. The partnership between these three research institutions will lead to innovative stem cell-based treatments.
• In June 2021, The Morrison Government announced an investment of USD 180 million in medical research projects around Australia to improve healthcare. 106 medical research projects, including studies regarding cancer, dementia, brain injuries, heart problems, and neurofibromatosis, will receive USD 20 billion Medical Research Future Fund. USD 18.7 million will be provided through the Stem Cell Mission for 17 projects addressing illnesses including heart disease, COVID-19, epilepsy, and childhood cancer.
• In November 2020, the Canadian Institutes of Health Research announced more than USD 30 million in investment over the next seven years, starting from 2020-2021, in a new research project. This project will be a part of the initiative ‘100 Years of Insulin: Accelerating Canadian Discoveries to Defeat Diabetes’. This will accelerate the development of stem cell-based therapies for treating Type 1 diabetes.
• In June 2020, nearly USD 228 million (EUR 200 million) was provided to help domestic research and manufacturing medicines. Additionally, the government launched the 4th Future Investment Plan of USD 22 billion (EUR 20 billion) for over five years (2021–2025), including an investment of USD 2.3 billion (EUR 2 billion) for the strategies related to digital health, biotherapy and bioproduction, and diseases infectious and emerging diseases (EID).

These investments and support for cell-based research activities increase the demand for cell culture reagents.

Key Findings of the Cell Culture Reagents Market Study

In 2022, the Growth Factors and Cytokines Segment is Expected to Dominate the Cell Culture Reagents Market

Based on product, in 2022, the growth factors and cytokines segment is estimated to command the largest share of the cell culture reagents market. Cytokines and growth factors are involved in signal transduction between the cells, which further help in cell survival and proliferation as well as exertion of cell functions. In life science, these are commonly used as agents for cell culture. Their high demand contributes to the large market share of this segment.

In 2022, the Bioproduction Segment is expected to Dominate the Cell Culture Reagents Market

Based on application, in 2022, the bioproduction segment is estimated to account for the largest share of the cell culture reagents market. The production and demand for biopharmaceuticals are rising due to the effectiveness of biopharmaceuticals in treating diseases. Additionally, increased vaccine production and approvals for monoclonal antibodies during the COVID-19 pandemic contributed to the large market share of this segment.

In 2022, the Pharmaceutical & Biotechnology Companies Segment is expected to Dominate the Cell Culture Market

Based on end user, in 2022, the pharmaceutical & biotechnology companies segment is estimated to account for the largest share of the cell culture reagents market. Major factors contributing to the large market share are this segment are the higher adoption of cell culture products in commercial and research bioproduction and relatively greater purchasing power compared to the other end users.

Asia-Pacific: Fastest-growing Regional Market

Based on geography, Asia-Pacific is expected to register the highest CAGR during the forecast period. The growing population is the key factor that drives this region's healthcare & pharmaceutical sector, which draws a lot of investment from government & non-government bodies. Asia-Pacific countries aim to become competitive in the global biotech market, paving the way for a lot of research & development activities in this domain. Additionally, the increasing investments propel the demand for cell culture reagents across the Asia-Pacific region.

Key Players

The key players profiled in the cell culture reagents market study are Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), PromoCell GmbH (Germany), Cytiva (U.S.), Lonza Group Ltd (Switzerland), Corning Incorporated (U.S.), Becton, Dickinson and Company (U.S.), HiMedia Laboratories (India), Sartorius AG (Germany), FUJIFILM Holdings Corporation (Japan), Agilent Technologies, Inc. (U.S.), Miltenyi Biotec B.V. & Co. KG (Germany), BIOLOGOS (U.S.), STEMCELL Technologies Inc. (Canada), and Cell Applications, Inc. (U.S.).

Scope of the Report:

Cell Culture Reagents Market, by Product

• Reagents
  • Growth Factors and Cytokines
  • Supplements
  • Cryoprotective Reagents
  • Antibiotics/Antimycotics
  • Cell Dissociation Reagents
  • Buffers & Chemicals
  • Balanced Salt Solutions
  • Contamination Detection Kits
  • Attachment and Matrix Factors
  • Other Cell Culture Reagents
    (Other cell culture reagents include chelators, antioxidants, sugars, vitamins, stains, and dyes)

Cell Culture Reagents Market, by Application

• Bioproduction
  • Monoclonal Antibody Production
  • Therapeutic Protein Production
  • Vaccine Production
  • Cell and Gene Therapy
• Diagnostics
• Cancer Research
• Drug Screening & Development
• Stem Cell Research

Cell Culture Reagents Market, by End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Diagnostic Laboratories

Cell Culture Reagents Market, by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • Rest of APAC (RoAPAC)
• Latin America
• Middle East & Africa

Key questions answered in the report: